Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Moonshiner592on May 19, 2020 7:15pm
170 Views
Post# 31048852

RE: More News To Come

RE: More News To Come

HighSkies2019 wrote: I think this is a valuable deal with the R107 and Klys 1012 .. R107 is already authorized to use in infants with lung issues and only needs a phase 1 to pass regulations in some countries.... I think Kly will use R107 to get their K1012 to market....and not sure if this news has any connection to Kly ...but in Canadian news yesterday our Govt announced the first approved on Saturday testing for a vaccine to start being tested..and will be done by health canada officials..which I noticed some mention of this in Kly NR today..and the canadian news it only noted it was with a Canadian listed venture ..normally they name the company ...and I also noticed that in kly NR it also stated that if this R107 works will be distributed in canada..Kly needs to update on payment to talent..echelon and our products and status re FDA b4 we buy another company with shares ..it seems kly jumped interest from their Gvhd program to covid interest in the nr...Salam company has been in business for 25 yrs with pertinent credentials...if they are willing to accept all share payment they must anticipate future value..... I personally will sit tight till i hear final NR... to be halted this long to June 15 there has to be more to process ... glta

 

Makes sense ... let's see 

<< Previous
Bullboard Posts
Next >>